S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
320. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate
cancer on androgen deprivation therapy. Journal of Urology 2000;163(6):1743-6.
http://www.ncbi.nlm.nih.gov/pubmed/10799173
321. Boustead G, Edwards SJ. Systematic review of early vs deferred hormonal treatment of
locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU Int
2007;99(6):1383-9. http://www.ncbi.nlm.nih.gov/pubmed/17346269
322. Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the
treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2001;(4):CD003506.
323. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen
progression after radical prostatectomy: what is the most appropriate cut point? Journal of
Urology 2001;165(4):1146-51. http://www.ncbi.nlm.nih.gov/pubmed/11257657
324. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Jr., Lilja H, Scardino PT.
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal
for a standardized definition. J Clin Oncol 2006;24(24):3973-8.
http://www.ncbi.nlm.nih.gov/pubmed/16921049
325. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining
PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology
2003;61(2):365-9. http://www.ncbi.nlm.nih.gov/pubmed/12597949
326. Roach M, III, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H.
Defining biochemical failure following radiotherapy with or without hormonal therapy in
men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO
Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-74.
http://www.ncbi.nlm.nih.gov/pubmed/16798415
327. Foster LS, Jajodia P, Fournier G, Jr., Shinohara K, Carroll P, Narayan P. The value of prostate
specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa
recurrences following radical prostatectomy. Journal of Urology 1993;149(5):1024-8.
http://www.ncbi.nlm.nih.gov/pubmed/7683341
328. Fowler JE, Jr., Brooks J, Pandey P, Seaver LE. Variable histology of anastomotic biopsies with
detectable prostate specific antigen after radical prostatectomy. Journal of Urology
1995;153(3 Pt 2):1011-4. http://www.ncbi.nlm.nih.gov/pubmed/7531783
329. Heidenreich A, Bolla M, Joniau S, van der Kwast TH, Matveev V, Mason MD, Mottet N, Schmid
HP, Wiegel T, Zattoni F, European Association of Urology (EAU). EAU guidelines on prostate
cancer. Arnhem: EAU; 2009.
330. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and
complications after salvage local therapy for postradiation prostate-specific antigen failure:
a systematic review of the literature. Cancer 2007;110(7):1417-28.
http://www.ncbi.nlm.nih.gov/pubmed/17694553
331. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.
Risk of prostate cancer-specific mortality following biochemical recurrence after radical
prostatectomy. JAMA 2005;294(4):433-9. http://www.ncbi.nlm.nih.gov/pubmed/16046649
332. Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and
salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 2007;84(2):197-
215. http://www.ncbi.nlm.nih.gov/pubmed/17532494
333. Loeb S, Roehl KA, Viprakasit DP, Catalona WJ. Long-term rates of undetectable PSA with
initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol
2008;54(1):88-94. http://www.ncbi.nlm.nih.gov/pubmed/18400368
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011